Julie Rubinstein, who serves as President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), completed a series of stock sales totaling $758,108 over the span of April 9 to April 13. The dispositions were carried out under a prearranged 10b5-1 trading arrangement and included trades at per-share prices reported between $12.75 and $14.44.
The company’s Form 4 filing with the Securities and Exchange Commission details each tranche. On April 9, Rubinstein sold 16,960 shares at prices ranging from $13.40 to $14.38, producing proceeds of $233,908. Also on April 9, an additional block of 2,100 shares was sold at prices between $14.40 and $14.62 for $30,324.
On April 10, Rubinstein sold 18,660 shares at prices from $12.43 to $13.42, generating $237,915. That same day she sold another 400 shares at prices between $13.44 and $13.53, adding $5,392. The final reported sales occurred on April 13, when she sold 15,722 shares at prices from $12.83 to $13.81 for $203,500, and 3,338 shares at prices between $13.87 and $14.22, totaling $47,069.
In conjunction with those sales, the filing shows Rubinstein exercised options to acquire 44,166 shares of Adaptive Biotechnologies common stock. The option exercises carried an aggregate cost of $328,956, with exercise prices reported between $7.27 and $8.46 per share.
Context and valuation note
The insider activity takes place against a backdrop in which ADPT shares have appreciated substantially over the past 12 months - the stock returned 78% over the prior year. At the same time, InvestingPro analysis cited in the record indicates that the shares are trading above their Fair Value estimate.
Earnings and analyst response
Adaptive Biotechnologies reported fourth-quarter 2025 results that exceeded analyst projections on both the earnings and revenue lines. The company posted an earnings per share (EPS) of -$0.09, versus an anticipated -$0.18. Revenue for the quarter was $71.7 million, which the filing notes is 20.85% higher than the expected $59.33 million.
Following the results, several brokerages adjusted their targets for the stock. TD Cowen raised its price target to $21.00 while keeping its existing rating. BTIG lifted its target to $22.00, citing robust expansion in the company’s Minimal Residual Disease (MRD) business, which grew 54% year-over-year in the fourth quarter and 46% for the full year. Piper Sandler reaffirmed an Overweight rating, projecting clonoSEQ volume growth of more than 30%, along with expanding margins and favorable reimbursement trends.
What this means for investors
The filings show Rubinstein both selling shares under a formal trading plan and exercising options to acquire stock at lower exercise prices. At the same time, ADPT’s recent operational results prompted analysts to raise price targets and emphasize growth in the company’s MRD franchise. Valuation commentary from InvestingPro included with the filings indicates a view that the stock was trading above Fair Value despite the recent upward price movement.
Investors evaluating the company will find both the insider transactions and the quarterly results relevant to assessing management positioning, recent performance trends, and analyst sentiment moving forward.